Eagle Pharmaceuticals (EGRX) Has Fallen 26% in Last One Year, Underperforms Market

If you are looking for the best ideas for your portfolio you may want to consider some of Del Principe O’Brien Financial Advisors top stock picks. Del Principe O’Brien Financial Advisors, an investment management firm, is bullish on Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) stock. In its Q2 2019 investor letter – you can download a copy here – the firm discussed its investment thesis on Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) stock. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) is a specialty pharmaceutical company.

In August 2019, Del Principe O’Brien Financial Advisors had released its Q2 2019 investor letter. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) stock has posted a return of -26.5% in the trailing one year period, underperforming the S&P 500 Index which returned 10.2% in the same period. This suggests that the investment firm was wrong in its decision. On a year-to-date basis, Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) stock has fallen by 31.0%.

In Q2 2019 investor letter, Del Principe O’Brien Financial Advisors said the fund posted a return of 7.1% in the second quarter of 2019, outperforming the S&P 500 Index which returned 4.30% in the same period. Let’s take a look at comments made by Del Principe O’Brien Financial Advisors about Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) stock in the Q2 2019 investor letter.

“In April of this year, Eagle announced that it was expanding its existing licensing agreement with Teva Pharmaceuticals for BENDEKA™ (bendamustine hydrochloride), an injectable drug used for treating patients with chronic lymphocytic leukemia or a certain type of non-Hodgkin lymphoma. This means Eagle will receive increasingly larger royalty payments from Teva for as long as the drug is sold in the U.S. Thanks to a decision issued by the FDA in February of this year, no other bendamustine product (including generics) can launch in the U.S. until December 2022. BENDEKA also has a strong patent portfolio that runs through 2033, which further increases the exclusivity of the drug.”


In Q1 2020, the number of bullish hedge fund positions on Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) stock increased by about 7% from the previous quarter (see the chart here), so a number of other hedge fund managers seem to agree with Eagle Pharmaceuticals’s growth potential. Our calculations showed that Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we leave no stone unturned when looking for the next great investment idea. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.